"Розувастатин": the instruction on application, responses. Cheap analogue of "Rosuvastatin"

The drug "Rosuvastatin" is known since 2003 and is offered as a statin of the IV generation. It is a modern and qualitative inhibitor of gamma-methylglutaryl-CoA reductase. This enzyme is responsible for the synthesis of cholesterol in the human body. Its inhibition leads to a decrease in endogenous cholesterol and a reduction in the risk of developing heart disease.

In addition to "Rosuvastatin," there are several other class analogues in the statin group. These are Simvastatin, Pravastatin, Cerivastatin, Lovastatin, Fluvastatin, Atorvastatin, and Pitavastatin. According to clinical efficacy and the rate of decrease in total and low-density cholesterol, "Rosuvastatin" is second only to "Pitavastatin", which is not yet widely used due to the less accumulated base of clinical studies.

To date, "Atorvastatin" is used more often than other statins due to the fact that it has the most comprehensive research base of evidence of its clinical effectiveness. He and his generics are also much cheaper than Rosuvastatin. But since the effect of the latter (normalization of the lipid profile of the blood plasma) is faster, then it begins to be applied more widely. This is really a quality drug, for which you should pay its price.

Place "Rosuvastatin" in pharmacotherapy

The preparation "Rosuvastatin" uses, in spite of the presence of class analogs, rather wide. It is determined by indications and is limited to contraindications. The indications are almost all types of hypercholesterolemia and disorders of fat metabolism. At the same time, a decrease in atherogenic lipid fractions has a positive effect on the body. Because of this, the likelihood of developing atherosclerotic lesions decreases, and the life expectancy (and its quality) increases somewhat.

The drug "Rosuvastatin" can be used both for the prevention of cardiovascular diseases, and for their treatment. The last niche of pharmacotherapy is due to the inhibition of atherosclerosis and the stabilization of the endothelium over the plaque. Since cerebral and heart infarctions develop due to acute thrombosis of the leading arteries, this clinical effect really helps to prevent acute coronary events.

Instructions for use

Attached to the drug "Rosuvastatin" instructions for use (analogues of such documentation are not available) contains a narrow range of indications for use. However, it does not contain information for the patient that before the application it is required to determine the cholesterol fractions. In the future, their change will allow to assess the clinical effectiveness of treatment in a certain dosage. Also, the instruction contains information about precautions and treatment features, about contraindications and the most frequent and important side effects.

Indications for use

Among all the diseases associated with increased lipid fractions of plasma, some clinical indications have been identified:

• Hereditary heterozygous (familial) hypercholesterolemia;
• Fredrickson classified polygenic hypercholesterolemia type IIa;
• Combined dyslipidemia classified by Fredrickson as IIb;
• Homozygous hereditary (familial) hypercholesterolemia;
• Coronary, cerebral or renal atherosclerosis, occluding the lumen of the artery;
• Atherosclerosis of lower limb arteries, including Lerish's syndrome ;
• Hypertriglyceridemia (type IV according to Fredrickson);
• Treatment of myocardial infarction and brain, beginning with an acute period;
• Prevention of myocardial infarction and stroke.

Contraindications

Any cheap analogue of "Rosuvastatin" has the same number of side effects as the original "Crestor". On their basis a spectrum of contraindications is formed, which look like this:

• Liver disease with cytolysis of hepatocytes and more than threefold increase in transaminase concentration;
• Hepatic insufficiency, cirrhosis of the liver with 9 points on the Child-Pugh scale;
• Chronic failure of renal function with a creatinine clearance less than 30 ml / min;
• Myopathy of any origin;
• Allergic reactions to the components of the dosage form or to "Rosuvastatin".

There is a group of additional contraindications for a dosage of 40 mg:

• Chronic renal failure with a creatinine clearance of at least 60 ml / min;
• Any hereditary myopathies;
• Simultaneous reception with fibrates;
• alcoholism;
• The Mongoloid race;
• The use of a statin for the first time.

Features of the drug

All "Rosuvastatin" - preparations, analogues of which are widely represented on the market. And, choosing a certain trade name, the patient should take this medication further. That is, to change medicine for another is unreasonable. The drug itself is taken regardless of food and at any time of the day. There are few other recommendations of specialists who previously worked with statins of the first generations. They contain information that you need to take statins before bed. Although this is of no fundamental importance, the main thing is that the medicine should be taken at about the same time and constantly.

Monitor your own condition continuously, while "Rosuvastatin" (analogues) is being accepted. Feedback from experts allows us to work out the best observation tactics. In particular, after establishing the presence of hypercholesterolemia, you need to start taking the drug in a fixed dose. After 2 months, the control is carried out - the lipidogram is repeatedly performed and the activity of aminotransferases is evaluated.

If normalization of the lipid profile of blood plasma is observed, it is required to continue taking the same dose. If total cholesterol remains high, and the amount of low-density cholesterol decreases slightly, an increase in dose is required. If transaminases increase three-fold, statins should be withdrawn. It is worth noting especially that the least propensity to cause cytolysis from all statins is "Rosuvastatin." Analogues (Ukraine is also gradually moving from "Atorvastatin" to "Rosuvastatin") in the class less safe. And the least studied is "Pitavastatin".

Analogues of "Rosuvastatin"

As analogues of "Rosuvastatin" ("Crestor") already today more than 10 preparations are offered. Among them, "Acorta", "Mertenil", "Rosart", "Rosystarc", "Rosuvastatin Canon", "Rosuvastatin Soteks", "Rosuvastatin SZ", "Rosulip", "Rosukard", "Roxera", "Rustor" Tevastor ". The cost of treatment by them is different, as is efficiency. The price of these drugs can be divided into three categories:

• Low prices (from 250 to 650 rubles): "Rosuvastatin SZ", "Rosuvastatin Kanon", "Acorta", "Rosuvastatin SOTEX";
• Average prices (from 400 to 900 rubles): "Mertenil", "Rosart", "Roxera", "Rosukard", "Tevastor", "Rosulip";
• High prices (from 1100 to 2200 rubles): "Cross".

The price analysis was carried out on the basis of a comparison of the cost of the preparations, the mass of the active substance in which was 10 mg. The price range reflects the cost of a one-month course of hypocholesterolemic therapy. The cheapest analogue of "Rosuvastatin" is produced by the company "Northern Star". "Rosuvastatin Canon" and "Akorta" also slightly differ in price. Their cost varies the least depending on fluctuations in exchange rates.

Overview of cheap generic "Krestor"

The drug "Rosuvastatin", released by Astrazeneca, is called "Crestor". This is an original medicine, with which all the others should be compared. The same goes for the feedback: the characteristic of a certain generic drug should be based on its comparison with "Krestor." But because of its high cost, many patients immediately begin treatment of hypercholesterolemia with cheaper generics.

Objective information in the reviews can be provided only by specialists who often encounter the use of generic "Rosuvastatin", and the original "Crestor." And attached to the drug "Rosuvastatin" instructions for use, patient feedback and clinical experience will allow other patients to choose the specific trade name.

Expert Reviews of "Krestore" and generics

Comparison of "Krestor" was carried out only by specialists of the All-Russian Society of Cardiology. This information is often published in the journal Rational Pharmacotherapy in Cardiology. In particular, it touches upon the questions of bioequivalence of generics to the drug "Krestor". According to the results of pharmacoeconomic studies it was found out that the preparations "Mertenil", "Rosart", "Roxera", "Rosukard" and "Rosulip" are bioequivalent to "Crestor".

This means that any indicated analogue of "Rosuvastatin" has a therapeutic effect similar to the original drug, it has the same number and severity of side effects. While the medications Rosuvastatin SZ, Rosuvastatin Kanon, Rosuvastatin Soteks and Akorta are not involved in such tests. Since these statistical studies are not financed by pharmacological companies, the information obtained is objective and corresponds to the clinical features of the treatment of hypercholesterolemia. However, the results are only for foreign generics.

Reviews of experts about cheap generics "Rosuvastatin"

The modern cheap analogue of "Rosuvastatin" must prove its bioequivalence to "Crestor", after which it automatically receives the respect of professionals. Without studies of bioequivalence, specialists can note only the clinical features of the application. One of them is this: with the constant use of cheap analogues of "Rosuvastatin" (the preparations are indicated above), the frequency of side effects is comparable to that observed with the use of generics equivalent to "Crestor".

Fluctuations in the plasma concentration of "rosuvastatin" arising from the use of a solid dosage form with another formulation are, in this case, considered insignificant. Therefore, the cheap Russian analogue of "Rosuvastatin" can really replace the original drug "Krestor" and its generics for the treatment of hypercholesterolemia.

Characteristics of patient feedback

According to reviews of patients who share their impressions about the use of drugs with the attending physician, it is possible to distinguish several natural conclusions. First, the judgments of patients about the quality of the drug are biased. Secondly, because of the patient's inconspicuous clinical effect, adherence to therapy is low, although treatment is necessary to prevent the risk of acute coronary events. Third, patients tend to exaggerate the importance of side effects and underestimate the dynamics of plasma lipidogram indices.